TY - JOUR
T1 - Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-A proof of principle study
AU - Hemsley, Kim M.
AU - Norman, Elizabeth J.
AU - Crawley, Allison C.
AU - Auclair, Dyane
AU - King, Barbara
AU - Fuller, Maria
AU - Lang, Debbie L.
AU - Dean, Caroline J.
AU - Jolly, Robert D.
AU - Hopwood, John J.
N1 - Funding Information:
The authors wish to acknowledge and thank Frazer Allan and Alastair Johnstone (IVABS, Massey University) for their expert assistance with the intra-CSF injections and the post-mortems, respectively. We also thank Ros Machon for undertaking the anesthesias; the IVABS Clinic staff for monitoring the recovery of the dogs; Stuart Hunter and Mike Hogan for assistance with the post-mortems; Pat Davey, Evelyn Lupton, Mary Gadam and Aaron Hicks for helping in the preparation of fixatives and in the cut-up of EM tissues and preparation and staining of paraffin sections, and Helen Beard for rhSGSH immunohistochemistry. The advice of Drs. Peter Meikle and Dallas Grasby (LDRU) and the assistance of Tina Rozaklis and Janina Pacyna with the protein quantification studies is much appreciated. Amanda Luck and Suzanne Brodie are thanked for their help in homogenizing some of the tissues for mass spectrometry. We are grateful to Drs. Mike Concino and Satyajit Ray at Shire Human Genetic Therapies for the preparation and purification of the rhSGSH. This work was supported by National Health and Medical Research Council of Australia (#399354 to JJH, KMH and ACC) and Shire Human Genetic Therapies (to JJH).
PY - 2009/12
Y1 - 2009/12
N2 - Mucopolysaccharidosis type IIIA (MPS IIIA) results from lack of functional sulfamidase (SGSH), a lysosomal enzyme. Its substrate, heparan sulfate, and other secondarily-stored compounds subsequently accumulate primarily within the central nervous system (CNS), resulting in progressive mental deterioration and early death. Presently there is no treatment. As a potential therapeutic strategy, recombinant human sulfamidase (rhSGSH) was administered into the CSF (via the cerebellomedullary cistern) of three adult MPS IIIA dogs either twice with a 4 day interval, or weekly for up to 4 weeks. The dogs were euthanased 24 h post-injection along with one untreated unaffected and two MPS IIIA controls. We have examined the three dimensional pattern of distribution of enzyme in the CNS and its ability to reduce primary substrate storage. High concentrations of rhSGSH protein, with up to 39-fold normal enzyme activity levels were detected within widespread areas of the CNS. RhSGSH protein was also detectable by immunohistochemistry in neurons and glia in all three enzyme-treated dogs. In both weekly-treated dogs, relative levels of a heparan sulfate-derived disaccharide, measured using tandem mass spectrometry, were lower in many brain regions when compared to untreated MPS IIIA controls. A moderately severe meningitis was also present as well as antibodies to rhSGSH in CSF/plasma. These findings demonstrate proof of principle that MPS IIIA can be treated by intracisternal enzyme replacement warranting further experiments in animals tolerant to rhSGSH. This enzyme delivery method may represent a means of treating neuropathology in MPS IIIA and other lysosomal storage disorders affecting the CNS. Crown
AB - Mucopolysaccharidosis type IIIA (MPS IIIA) results from lack of functional sulfamidase (SGSH), a lysosomal enzyme. Its substrate, heparan sulfate, and other secondarily-stored compounds subsequently accumulate primarily within the central nervous system (CNS), resulting in progressive mental deterioration and early death. Presently there is no treatment. As a potential therapeutic strategy, recombinant human sulfamidase (rhSGSH) was administered into the CSF (via the cerebellomedullary cistern) of three adult MPS IIIA dogs either twice with a 4 day interval, or weekly for up to 4 weeks. The dogs were euthanased 24 h post-injection along with one untreated unaffected and two MPS IIIA controls. We have examined the three dimensional pattern of distribution of enzyme in the CNS and its ability to reduce primary substrate storage. High concentrations of rhSGSH protein, with up to 39-fold normal enzyme activity levels were detected within widespread areas of the CNS. RhSGSH protein was also detectable by immunohistochemistry in neurons and glia in all three enzyme-treated dogs. In both weekly-treated dogs, relative levels of a heparan sulfate-derived disaccharide, measured using tandem mass spectrometry, were lower in many brain regions when compared to untreated MPS IIIA controls. A moderately severe meningitis was also present as well as antibodies to rhSGSH in CSF/plasma. These findings demonstrate proof of principle that MPS IIIA can be treated by intracisternal enzyme replacement warranting further experiments in animals tolerant to rhSGSH. This enzyme delivery method may represent a means of treating neuropathology in MPS IIIA and other lysosomal storage disorders affecting the CNS. Crown
KW - Canine disease model
KW - Cerebrospinal fluid
KW - Enzyme replacement therapy
KW - Intracisternal delivery
KW - Lysosomal storage disorder
KW - Mucopolysaccharidosis type IIIA
KW - Sanfilippo
UR - http://www.scopus.com/inward/record.url?scp=70350620535&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2009.07.013
DO - 10.1016/j.ymgme.2009.07.013
M3 - Article
C2 - 19699666
AN - SCOPUS:70350620535
VL - 98
SP - 383
EP - 392
JO - Molecular Genetics and Metabolism
JF - Molecular Genetics and Metabolism
SN - 1096-7192
IS - 4
ER -